• 1
    Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 36681.
  • 2
    Sutcliffe S, Platz EA. Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol Oncol 2007; 25: 2429.
  • 3
    Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 2005; 173: 196974.
  • 4
    Bojar RA, Holland KT. Acne and Propionibacterium acnes. Clin Dermatol 2004; 22: 3759.
  • 5
    Alexeyev O, Bergh J, Marklund I, Thellenberg-Karlsson C, Wiklund F, Gronberg H, Bergh A, Elgh F. Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control 2006; 17: 112733.
  • 6
    Galobardes B, Davey Smith G, Jeffreys M, Kinra S, McCarron P. Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am J Epidemiol 2005; 161: 1094101.
  • 7
    Giles GG, Severi G, English DR, McCredie MR, MacInnis R, Boyle P, Hopper JL. Early growth, adult body size and prostate cancer risk. Int J Cancer 2003; 103: 2415.
  • 8
    Lightfoot N, Conlon M, Kreiger N, Sass-Kortsak A, Purdham J, Darlington G. Medical history, sexual, and maturational factors and prostate cancer risk. Ann Epidemiol 2004; 14: 65562.
  • 9
    Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 25865.
  • 10
    Andrews GC, Domonkos AN. Treatment of acne vulgaris. JAMA 1951; 146: 110713.
  • 11
    Pillsbury DM, Shelley WB, Kligman AM. Dermatology. Philadelphia: W. B. Saunders, 1956.
  • 12
    Bobroff A. Acne and related disorders of complexion and scalp. Springfield, IL: Charles C. Thomas, 1964.
  • 13
    Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 15718.
  • 14
    Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003; 95: 10047.
  • 15
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998; 9: 39.
  • 16
    Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 647.
  • 17
    Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 4427.
  • 18
    Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 8939.
  • 19
    Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. A prospective cohort study of vasectomy and prostate cancer in US men. JAMA 1993; 269: 8737.
  • 20
    Platz EA, Leitzmann MF, Rimm EB, Willett WC, Giovannucci E. Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am J Epidemiol 2004; 159: 44453.
  • 21
    Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 2001; 12: 55767.
  • 22
    Hodson G. Rosacea, including seborrhoea oleasa, acne vulgaris and hyperidrosis. In: Mitchell-HeggsGB, ed. Modern practice in dermatology. New York: Paul B. Hoeber, 1950; 20520.
  • 23
    Cunliffe WJ, Gollnick HPM. Acne: diagnosis and management. London: Mark Dunitz, 2001.
  • 24
    Shannon BA, Garrett KL, Cohen RJ. Links between Propionibacterium acnes and prostate cancer. Future Oncol 2006; 2: 22532.
  • 25
    Burkhart CG, Burkhart CN, Lehmann PF. Acne: a review of immunologic and microbiologic factors. Postgrad Med J 1999; 75: 32831.
  • 26
    Webster GF. Inflammation in acne vulgaris. J Am Acad Dermatol 1995; 33: 24753.
  • 27
    De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG. Human prostate cancer precursors and pathobiology. Urology 2003; 62: 5562.
  • 28
    Chambers H. Antimicrobial agents (continued): protein synthesis inhibitors and miscellaneous antibacterial agents. In: HardmanJ, LimbirdL, GilmanA, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 10th edn. New York: McGraw-Hill, 2001. 193971.
  • 29
    Wyatt E, Sutter S, Drake L. Dermatological pharmacology. In: HardmanJ, LimbirdL, GilmanA, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 10th edn. New York: McGraw-Hill, 2001; 1795818.
  • 30
    Ristuccia AM, Cunha BA. Current concepts in antimicrobial therapy of prostatitis. Urology 1982; 20: 33845.
  • 31
    Leigh DA. Prostatitis—an increasing clinical problem for diagnosis and management. J Antimicrob Chemother 1993; 32( Suppl A): 19.